Abstract: Disclosed herein are engineered yeast cells, systems, and methods for screening for a ligand that modulates a receptor function and for determining functional consequences of receptor-ligand binding.

Abstract: In some aspects, the disclosure is directed to methods and systems for in-application dynamic content loading via a hybrid process, including both local and remote content items, via a content handler intercepting requests in a predetermined uniform resource locator (URL) scheme and redirecting the requests to local storage or a remote content provider, transparently to a browser application or webview of the application, and avoiding restrictions imposed by an operating system of the device. Content may be dynamically updated on the content provider server by developers, and dynamically loaded during execution of the application on client devices, without requiring updates to be provided to an application store or publisher server.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: A bypass control apparatus is used with a pump pumping a fluid therethrough. A bypass flow line circulates fluid about the pump. A bypass valve is interposed in the bypass flow line and moves between an opened state to permit the fluid to circulate through the bypass flow line back to the pump and a closed state to prevent the fluid from circulating through the bypass flow line. A sensor determines an existing flow-through rate of the fluid flowing through the pump. The controller communicates with the sensor and the bypass valve and moves the bypass valve to the closed state when determined that the existing flow-through rate of the fluid through the pump is at least a predetermined flow-through rate and moves the bypass valve to the opened state when determined that the existing flow-through rate of the fluid through the pump is less than the predetermined flow-through rate.

Abstract: A Toll-IL-1-resistance (TIR) domain-containing adaptor-inducing IFN-? (TRIF)-related adaptor molecule (TRAM) has been identified. TRAM acts specifically in the TLR4 signaling pathway. The invention includes compounds useful for modulating TLR signaling by modulating the effects of TRAM.

Abstract: Trocar assembly devices are disclosed that include an improved elastomeric seal member to maintain sealing engagement during off-centering or radial motion of instruments extending therethrough. The seal members include an inner section and an outer section. The inner section has an opening formed therein to permit an elongate instrument to pass therethrough in sealing engagement therewith. In accordance with certain embodiments, a corrugated portion is formed in the outer section. In accordance with certain embodiments an annular floating ring separates the inner section from the outer section.

Abstract: Trocar assembly devices are disclosed that include an improved elastomeric seal member to maintain sealing engagement during off-centering or radial motion of instruments extending therethrough. The seal members include an inner section and an outer section. The inner section has an opening formed therein to permit an elongate instrument to pass therethrough in sealing engagement therewith. In accordance with certain embodiments, a corrugated portion is formed in the outer section. In accordance with certain embodiments an annular floating ring separates the inner section from the outer section.

Abstract: Trocar assembly embodiments are disclosed that include a trocar tube and a housing defining a chamber adjoining a proximal end portion of the trocar tube. An elastomeric seal member is positioned within the chamber for sealing the chamber as an elongate instrument passes through an opening formed in the seal member. A seal/protector assembly is positioned in the chamber proximally of the seal member in facing relationship to the seal member. The protector assembly includes at least two axially aligned protector members, each of which has an annular collar portion and at least one leaf portion formed integrally with the collar portion so as to form a living hinge portion. The leaf portions define an opening therethrough in axial alignment with the opening in the seal member.